During the past decade, Instytut Genetyki i Immunologii GENIM conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Instytut Genetyki i Immunologii GENIM" are "HER2 Exon 20 Mutation" (1 trials), "KRAS p, G12c Mutated /Advanced Metastatic NSCLC" (1 trials), "Non-squamous NSCLC" (1 trials), "Solid Tumours" (1 trials) and "Squamous-Cell Non-Small-Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Instytut Genetyki i Immunologii GENIM" in a lesser frequency.

Most popular intervention types in "Instytut Genetyki i Immunologii GENIM" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (3 trials), "AMG 510" (1 trials), "Bemarituzumab" (1 trials), "Carboplatin" (1 trials) and "Nab-paclitaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instytut Genetyki i Immunologii GENIM" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Instytut Genetyki i Immunologii GENIM". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Instytut Genetyki i Immunologii GENIM, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Instytut Genetyki i Immunologii GENIM, 1 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".